Your session is about to expire
← Back to Search
APL-1202 + Tislelizumab for Bladder Cancer (ANTICIPATE Trial)
ANTICIPATE Trial Summary
This trial is testing a new combination therapy for patients with bladder cancer who are ineligible or refuse cisplatin-based chemotherapy.
ANTICIPATE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowANTICIPATE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ANTICIPATE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread and can be measured.I have or had an optic nerve disorder.I have active tuberculosis.I haven't been in a clinical trial or taken experimental drugs in the last 4 weeks.I have not had severe infections or been hospitalized for infection complications in the last 4 weeks.I do not have any major health issues that could interfere with the study.I haven't had major surgery in the last 4 weeks and don't expect to need any during the study.I have been diagnosed with idiopathic pulmonary fibrosis.I have not received a vaccine in the last 4 weeks and do not expect to need one during the study.I haven't taken any immune-boosting drugs in the last 4 weeks.My bladder cancer is mostly transitional cell type.I haven't taken more than 10 mg/day of steroids like prednisone in the last 4 weeks.I am scheduled for a major bladder surgery as recommended.I am 18 years old or older.I have had treatment for bladder cancer that went through my whole body.I do not have serious heart problems like recent heart attacks or unstable heart rhythms.I have had a previous transplant of stem cells or an organ.I am allergic to certain medications made in Chinese hamster ovary cells.You have a history of serious allergic reactions to certain types of medications made from antibodies or proteins.I have an autoimmune thyroid condition but am on a stable medication dose.I have a history of autoimmune disease.My Type 1 diabetes is not under control.I haven't had cancer other than bladder cancer in the last 5 years, except for certain low-risk types.I have high calcium levels in my blood that require treatment.I have or had a cataract.I have been treated with drugs targeting PD-1 or PD-L1.I have an untreated hepatitis infection.You have tested positive for HIV.
- Group 1: APL-1202 in combination with tislelizumab
- Group 2: Tislelizumab alone
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this research still ongoing?
"As indicated by clinicaltrials.gov, this medical study is still open for recruitment as of today. It was initially posted on December 28th 2021 and has been updated more recently on February 21st 2022."
Is there precedent for this kind of clinical trial?
"As of present, there are 105 active trials for APL-1202 combined with tislelizumab in 426 cities and 45 nations. The first trial was conducted by BeiGene in 2017 and involved 805 participants who completed its Phase 3 approval phase. Following the initial run, a further 11 studies have been concluded."
How many participants are being incorporated in this research experiment?
"Affirmative. Clinicaltrials.gov presents evidence that this research is in the midst of recruitment, with 79 volunteers sought from 1 site since its first posting on December 28th 2021 and last editing on February 21st 2022."
What is the major goal of this clinical test?
"This protocol will track two primary outcomes over a 26 month period: adverse events (AE) and serious adverse events (SAE). Secondary measurements include Tmax, Ae%, and plasma ctDNA-based tumor mutation burdens (TMB)."
Are there any other investigations conducted regarding the concomitant use of APL-1202 and tislelizumab?
"At present, there are 105 active clinical trials for APL-1202 and tislelizumab therapy, with 18 of those studies in their final phase. Trials are being conducted mainly in Nanning, Guangxi; however, 2329 other locations also have these experiments underway."
Share this study with friends
Copy Link
Messenger